Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ('Tonix” or the 'Company”), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase ...
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Exploring clinical development plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback